Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Generic Isotretinoin Risk Program To Use BU’s Slone Epidemiology

Executive Summary

Mylan generic isotretinoin risk management will be conducted at the Slone Epidemiology Unit of Boston University School of Public Health, the same institution Roche has been using for its risk management program for Accutane

You may also be interested in...



Cardinal Manufacturing Helped By FDA Compliance Crackdown, Firm Says

FDA's crackdown on pharmaceutical GMP compliance is expanding the outsourcing opportunities for contract manufacturers, Cardinal Health Life Sciences Products & Services President George Fotiades told the J.P. Morgan H&Q conference in San Francisco Jan. 7

Cardinal Manufacturing Helped By FDA Compliance Crackdown, Firm Says

FDA's crackdown on pharmaceutical GMP compliance is expanding the outsourcing opportunities for contract manufacturers, Cardinal Health Life Sciences Products & Services President George Fotiades told the J.P. Morgan H&Q conference in San Francisco Jan. 7

Mylan Generic Isotretinoin Price Will Be 90% Of Roche Accutane AWP

Mylan's branded generic isotretinoin Amnesteem will be priced at 90% of the average wholesale price of Roche's Accutane

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040773

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel